From Discovery To Development To Delivery
AZBio is committed to building a top-tier life science industry in Arizona.
Arizona’s bioscience industry has grown in recent years and by 2014 state bioscience firms employed just over 24,000 in nearly 1,300 business establishments. Four of the state’s five bioscience subsectors have contributed to its 2 percent overall employment gain since 2012, led by double-digit job growth in medical devices (up 11 percent). State academic institutions accounted for nearly $400 million in bioscience-related R&D expenditures in 2014 and NIH funding to these and other non-academic institutions totaled $150.6 million in 2015. Arizona inventors have had 1,751 patents issued in bioscience-related classes since 2012, primarily in medical and surgical devices but also in drugs and pharmaceuticals, microbiology and genetics, and in biochemistry. The state has seen a strong increase in venture capital invested in bioscience-related companies in recent years. (Get The Facts)
AZBio Members Are Making LIFE Bettter
AZBio Members discover, develop, and deliver life-saving and life-changing innovations.
Get Connected With Arizona's Bioindustry
A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry. AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.
Success Stories – Good News from Arizona’s BioIndustry
News and events for Arizona’s Biotech Community
A team led by UA Cancer Center researchers Agnieszka Witkiewicz, MD, and Erik Knudsen, PhD, screened for drugs that could target triple-negative breast cancer tumors, producing several new therapeutic candidates for this difficult-to-treat cancer.
A Tempe bioscience firm selling its DNA analysis kits to 25 countries worldwide is expanding into the education sector.
NuvOx Pharma, a clinical stage biotechnology company, announces that the FDA has allowed a Phase II clinical trial in 60 stroke patients to proceed to test NuvOx’s investigational drug product, dodecafluoropentane emulsion (DDFPe).